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and the decrease in AF-QoL score, particularly in paroxysmal and persistent AF 
patients. CONCLUSIONS: The main impact on HRQoL in AF patients was not          
 conditioned by the type of AF, but the clinical presentation, especially number and 
frequency of symptoms.
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OBJECTIVES: To describe the experience with upper gastrointestinal (GI) symptoms, 
the impact of symptoms on daily life, and nonadherence and discontinuation of low-
dose acetylsalicylic acid (ASA) treatment in patients with cardiovascular (CV) risk. 
METHODS: Twenty-two patients from the US were selected to undergo face-to-face, 
1-hour qualitative interviews following a multicentre 3-month observational study of 
patients q18 years at risk of or with CV disease, about to begin or previously pre-
scribed daily low-dose ASA (75–325 mg) within 5 years (ClinicalTrials.gov identiﬁer: 
NCT00681759; AstraZeneca study code: D961FC00004). Interviewee-selection was 
based on low-dose ASA history, CV risk, GI medication use, and the occurrence of 
q1 upper GI event during the study period. Interviews were semi-structured and were 
audio-recorded and transcribed for analysis. RESULTS: 16 interviews were evaluable 
(mean age 44.7 years; 68.8% women); 6 patients were excluded following technical 
failure or violation of inclusion/exclusion criteria. Commonly reported upper GI 
symptoms were: burning feeling behind the breastbone (n  9); burning feeling in the 
upper stomach (n  4); acid taste in the mouth (n  4); regurgitation (n  4). Upper 
GI symptoms negatively impacted aspects of patients’ lives, including: food intake 
(n  12); sleep quality (n  6); emotions (n  5). Most patients reported occasional 
over-the-counter medication use; many altered their diet to manage upper GI symp-
toms. Overall, ﬁve patients reported treatment nonadherence. Upper GI symptoms 
caused nonadherence in 3 patients; 2 missed doses when GI symptoms were severe, 
despite being aware of low-dose ASA beneﬁts. Patients who understand the purpose 
of their low-dose ASA prescription could articulate the importance of adherence and 
the intention to continue therapy. CONCLUSIONS: Patients who understand the 
purpose of low-dose ASA treatment are more likely to adhere to therapy, although 
doses may be intentionally missed due to upper GI symptoms.
PCV148
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS  
WITH HYPERCHOLESTEROLEMIA
Müller-Nordhorn J1, Englert H2, Wegscheider K3, Berger H4, Völler H5, Katus HA6,  
Willich SN1
1Charité University Medical Center, Berlin, Germany, 2University of Applied Sciences, 
Münster, Germany, 3Department of Medical Biometry and Epidemiology, Hamburg, 
Germany, 4University of Applied Sciences, Osnabrück, Germany, 5Klinik am See, Rüdersdorf, 
Germany, 6Department of Cardiology, Heidelberg, Germany
OBJECTIVES: In patients with chronic diseases such as hypercholesterolemia, health-
related quality of life (HRQoL) is an important outcome. The objective of the present 
study was to determine factors associated with an impaired HRQoL after 12 months. 
METHODS: Patients with hypercholesterolemia were prospectively included in the 
ORBITAL (Open-label primary care study: Rosuvastatin-Based compliance Initiatives 
linked To Achievement of LDL goals) Study. Inclusion criteria were hypercholestero-
lemia with an indication for statin therapy according to the European Guidelines. 
Follow-up was 12 months. A total of 1961 primary care practices in Germany par-
ticipated. HRQoL was assessed with the Short Form (SF)-12 health status instrument. 
RESULTS: Of the 7640 patients included, 47% were high-risk patients in the primary 
prevention of coronary heart disease, 42% were patients with coronary heart disease, 
and 11% did not have a priori risk stratiﬁcation. Physical SF-12 summary scores were 
inversely associated with risk stratum, however, there was no such association between 
mental SF-12 summary scores and risk stratum. An impaired physical SF-12 score was 
associated with increased age, lower educational level, higher body mass index, 
smoking, existing coronary heart disease, a history of stroke, or a clinical event during 
follow-up. An impaired mental SF-12 score was associated with younger age, hyper-
tension, or a clinical event during follow-up. CONCLUSIONS: HRQoL in patients 
with hypercholesterolemia is associated with socioeconomic factors, lifestyle, and 
clinical events. Effective prevention is thus not only essential for clinical outcome 
but also for the maintenance of HRQoL in patients with hypercholesterolemia. 
ClinicalTrials.gov Identiﬁer: NCT00379249.
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OBJECTIVES: The assessment of quality of life among ambulatory patients with 
hypertension (HTN), diabetes type 2 (DM2) or coexisting HTN and DM2 
(HTNDM2). METHODS: Patients of 4 ambulatory care setting in Cracow (Poland) 
with HTN, DM2 or HTNDM2 were included. Polish versions of SF-36v.2 and EQ-
5D were used with the supplementary questions about age, gender, education, body 
mass, place of residence. Student’s t-test was used to compare the differences between 
paired groups. RESULTS: A total of 135 patients were included (68 with HTN, 22 
with DM2, 45 with HTNDM2); 57,8% of patients were women. 31,11% of patients 
with HTNDM2, 36,77% of patients with HTN and 72,73% of patients with DM2 
assessed their health status as well, none indicated the answer excellent or very good. 
Usually women indicated their QOL lower than men (HTN: PF, RP, PCS p  0,05; 
HTNDM2: PF, PB p  0,05). PCS was rated lower or similar to MCS; HTN: PCS 
39,30 o 7,88, MCS 40,45 o 10,96, DM2: PCS 42,77 o 8,22, MCS 42,23 o 9,86; 
HTNDM2: PCS 38,89 o 9,05, MCS 42,66 o 10,66. Due to EQ-5D 80% of patients 
had no problems with self care and 60% – with usual activities. Over 85% of patients 
had moderate or extreme pain or discomfort, more than 70% of patients felt moder-
ately or extremely anxious or depressed. About 75% of patients with HTN and 
HTNDM2 conﬁrmed problems with walking around. On VAS scale, patients with 
HTN, DM2 and HTNDM2 assessed their health state accordingly: 54,87 o 15,70, 
59,14 o 21,06, 55,56 o 14,50, with no statistically signiﬁcant differences between 
diseases and sexes. CONCLUSIONS: Patients with HTN and HTNDM2 estimated 
their quality of life lower than patients with DM2.
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OBJECTIVES: To investigate the differences in work productivity in patients with 
metabolic syndrome across three geographies. METHODS: Data from the 2008 
National Health and Wellness Survey (NHWS), an annual internet survey of attitudes, 
behaviors, health status, and outcomes of adults in the US, EU (Germany, Spain, Italy, 
UK, and France), and Japan (JPN) were used for the analysis. Metabolic syndrome 
was deﬁned as having at least three of the following: diabetes, BMI  30, high cho-
lesterol, or hypertension. Multiple regressions were used to determine the effect of 
geography on work productivity using the validated Work Productivity and Activity 
Impairment Questionnaire (WPAI) controlling for age, gender and total number of 
comorbidities. RESULTS: Of the 3,995 employed patients with metabolic syndrome 
in the analysis 881 (22.1%) were from Europe, 89 (2.2%) from JPN, and 3,025 
(75.7%) from the US. EU patients (10.9%) had signiﬁcantly higher levels of percent 
work missed in the past week due to health (absenteeism) than US (6.2%) and JPN 
(5.3%) patients. No signiﬁcant differences amongst geographies were seen for percent 
impairment at work (presenteeism), however, EU patients had higher levels of percent 
overall work impairment compared to US patients (p  0.05). For all metabolic 
patients (n  11,131) activity impairment was signiﬁcantly lower for JPN compared 
with US and EU (p  0.05). After controlling for age, gender and number of comorbid 
conditions, the differences remained signiﬁcant, with EU having higher absenteeism, 
overall work impairment, and activity impairment than the US, and JPN reporting 
less activity impairment than the US (p  0.05). CONCLUSIONS: The effect of meta-
bolic syndrome on work productivity differed signiﬁcantly across the three geogra-
phies. Any combination of factors may explain these differences: awareness of the 
condition, treatment differences, cultural issues, and health systems, amongst other. 
Further research is needed to describe the impact metabolic syndrome may have 
globally.
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OBJECTIVES: Although cardiovascular disease remains a major cause of death and 
morbidity in western countries, statins are well recognized for their role in prevention. 
The on-going need to maintain cost-effective health care has led to greater use of 
policy-driven therapeutic substitution programs for statins; however the impact of 
these policies on patients is often under-reported. METHODS: A review of published 
literature describing the impact of policy-driven statin switch programs was conducted 
based on a MEDLINE search [using the following terms: Hydroxymethylglutaryl-CoA 
Reductase Inhibitors (MeSH), and statin, switch, interchange, substitute, substitution 
(all ﬁelds); limited to English language and 1989–2009] and a review of reference lists 
from selected papers. RESULTS: Twenty-three studies were identiﬁed. Seventeen 
studies evaluated the impact of a “switch down” to equal or less potent statins. 6 
studies evaluated the impact of a “switch up” to more potent statins. Following 
introduction of “switch down” programs, 23–47% of patients were not eligible or 
willing to switch (7 studies), 17–38% of patients were switched to a non-equivalent 
(lower) dose of the new statin (3 studies), 4–11% of patients switched back to their 
original statin (5 studies), and switched patients were 19–33% less likely to be adher-
ent to therapy compared to those with no switch. Persistence was signiﬁcantly reduced 
among switch patients (2 studies). No signiﬁcant trend in lipid levels was noted (12 
studies) but loss of target levels was reported in 7–20% of patients (2 studies) and 3 
studies reported an increase in vascular events or death after switching. Studies evalu-
ating “switch up” programs consistently demonstrated improved reductions in lipid 
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levels (6 studies) and greater proportions of patients achieving LDL goals (5 studies). 
CONCLUSIONS: Policy-driven programs that encourage wide-spread switching of 
statins without consideration of patient-speciﬁc circumstances may impact the delivery 
of patient care and treatment outcomes.
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OBJECTIVES: To determine the effect of an employer-sponsored pharmacist-provided 
medication therapy management program (MTMP) on clinical outcomes and social 
measures in patients with hypertension. METHODS: A prospective, intent-to-treat, 
pre-post longitudinal study. Patients were Lucas County employees and/ dependents 
with a diagnosis for hypertension. The face-to-face MTMP was provided by pharma-
cists from the Toledo Area Coalition of Independent Pharmacies at seven pharmacies. 
JNC-VII guidelines were used to design interventions and set patient goals. Interven-
tions were provided every six months. Information recorded included demographic 
information, clinical markers and social measures. Data was documented by pharma-
cists or pharmacy technicians using intake forms. Data was analyzed using SPSSv 16.0 
for two groups i.e. hypertension only (may have other comorbid conditions excluding 
diabetes) and hypertensive diabetics. Wilcoxon signed-rank test was used to compare 
2 time points and the Friedman test was to compare readings at baseline, six and 12 
months. RESULTS: Two hundred and twenty eight patients have enrolled in the 
program. For the hypertension only group, mean systolic blood pressure (SBP) 
improved from 133.73 o 17.36 to 130.86 o 16.49 (p  0.112). For uncontrolled 
hypertensive patients in this group, mean SBP improved from 152.54 o 11.80 to 
139.77 o 18.22 (p  0.000). Diastolic blood pressure improved from 99.330 to 91.50 
(p  0.049). For hypertensive diabetic patients mean SBP decreased from 135.64 o 
18.21 to 127.55 o 15.26 (p  0.003). Signiﬁcant decrease was also observed for 
hypertensive diabetic with uncontrolled blood pressure at baseline (146.26 o 13.55 to 
131.44 o 13.66 mmHg; p  0.000). Mean alcohol and caffeine consumption decreased 
non-signiﬁcantly for patients in both groups. CONCLUSIONS: Pharmacists interven-
tions assisted uncontrolled patients in reaching their goal BP reading, and for con-
trolled patients, helped in maintaining their level of control. Periodic monitoring by 
a pharmacist can assist patients in reaching their targeted goal and maintaining that 
value so as to prevent long-term complications and costs.
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OBJECTIVES: African American men have lower hypertension control rates and 
higher cardiovascular disease mortality rates than those of Caucasian males. We 
examined how a peer approach to hypertension management could improve blood 
pressure control for participants, mostly minority males. METHODS: This is a longi-
tudinal cohort study. Patients in the intervention group enrolled relatives or friends 
in the hypertension education program and attended as teams, the monthly education 
sessions. Patients in the control group followed standard of care. Blood pressure was 
taken by a nurse, at baseline and every 3 months, for up to 15 months. Other clinical 
and behavioral information was obtained from medical charts and surveys at baseline 
and follow-up visits. We used survival analysis to compare time to achieve the deﬁned 
goal (patients without diabetes: systolic blood pressure (SBP)  140, patients with 
diabetes: SBP  130) between the two groups controlling for confounders and clusters 
of patients. RESULTS: A total of 250 subjects were included in the study; half in the 
intervention group. Approximately 90% of the participants were African American 
and 60% were males. The baseline blood pressure levels were 149/88 mmHg and 
146/88 mmHg in the control and intervention group (p  0.25). After controlling 
baseline blood pressure, gender, race, age, diabetes, smoking and patient clusters, we 
found that patients in the intervention group reached goal at a rate 4.97 times (95% 
CI: 2.02–12.25) higher than the rate in the control group. However, higher baseline 
SBP (HR  0.96, 95% CI: 0.93–0.98), males (HR  0.54, 95% CI: 0.31–0.95) and 
smoking (HR  0.39, 95% CI: 0.20–0.77) were signiﬁcantly associated with longer 
time to achieve the goal. CONCLUSIONS: Patients who approached hypertension 
management with their peers were much more likely to achieve blood pressure control 
in a shorter time than patients in standard of care. These ﬁndings have implications 
for clinical and public health interventions.
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OBJECTIVES: In 2004 and 2005, Menzis, a Dutch health insurance, company stimu-
lated physicians in prescribing cheaper versions of statins and proton pump inhibitors 
by offering ﬁnancial incentives to physicians who could reach speciﬁc annual prescrib-
ing thresholds (preference policy). The objective of this research is to quantify the 
effect of the preference policy of Menzis on the utilization/demand of statins in the 
Northern part of The Netherlands. Furthermore, we test the hypothesis of a signiﬁcant 
difference in the increase of simvastatin starters between Menzis and the other insur-
ance companies potentially due to the preference policy. METHODS: Prescription 
data originating from the Northern The Netherlands on the amount of simvastatin 
starters and simvastatin market share were extracted from IADB.nl, an in-house pre-
scription database of the University of Groningen. State-space analysis was used in 
order to estimate the effect of the preference policy. The Kalman ﬁlter was applied on 
an intervention state space model, followed by diagnostic tests for the independence, 
homoscedasticity and normality of the standardized prediction errors. RESULTS: A 
sharp increase in the level as well as in the trend of the market share of simvastatin 
around the last trimester of 2004 was observed, corresponding to the time point when 
the preference policy was initiated. A steep increase was apparent also on both the 
amount of Menzis clients that started use of simvastatin, as well as on the market 
share of simvastatin among Menzis clients. The interventions had a signiﬁcant, 
decreasing effect on the cost of simvastatin treatment. CONCLUSIONS: The prefer-
ence policy resulted in an increase of prescribing for simvastatin, the cheaper statin 
alternative, which consequently resulted in a decrease in cholesterol lowering treat-
ment costs.
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OBJECTIVES: In 2006, US Medicare created a new drug beneﬁt (Part D) for older 
adults. Part D cut down the number of older adults lacking drug coverage and reduced 
out-of-pocket costs, yet little is known about its effect on treatment of speciﬁc condi-
tions. Given Medicare’s role in ﬁnancing 20% of US and 9% of global pharmaceutical 
expenditures it is important to evaluate its effects. We examined Part D’s effect on 
drug utilization for congestive heart failure (CHF), a condition with substantial mor-
bidity and mortality. METHODS: Quasi-experimental study using insurance claims 
data from 7201 older adults with CHF continuously enrolled in a Medicare plan in 
2004–07. Three intervention groups with either no or limited drug coverage in 2004–
05 (US$600 or US$1400 annual limits) who obtained Part D drug beneﬁts in 2006 
were compared with a group with generous pharmacy beneﬁts throughout 2004–07. 
We estimated Part D’s effect on CHF drug utilization and adherence, adjusting 
for differences in sociodemographic and health status measures. RESULTS: Part D 
was associated with a 37% (95% CI 31–43%) increase in CHF prescriptions ﬁlled by 
the group previously lacking coverage, and increases of 10% (95% CI 6–12) and 7% 
(95% CI 6–8%) in the groups with limited prior coverage, relative to comparison 
group. The group previously lacking coverage was more likely to be adherent to 
angiotensin-converting enzyme inhibitors (ratio of odds ratios 2.20, 95% CI 1.65–
2.88) and beta blockers (ratio of odds ratios 2.56, 95% CI 1.95–3.35) after Part D 
relative to comparison group. Groups with limited prior drug coverage experienced 
statistically signiﬁcant, if smaller, improvements in adherence. CONCLUSIONS: 
Medicare Part D was associated with signiﬁcant improvements in adherence to phar-
macotherapy for CHF, the magnitude of which varied with the level of prior drug 
coverage. These ﬁndings have implications for health systems contemplating drug 
coverage expansions.
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OBJECTIVES: Market concentration of products affects competition, and thus is a 
key concern of marketing ﬁrms, policy makers, and regulators. Angiotensin converting 
enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers(ARBs) are two 
classes of hypertensive drugs, competing for one of the largest and most proﬁtable 
pharmaceutical market in the US. However, little is known about how market con-
centration affects the consumption of these drugs. We sought to measure the concen-
tration of drugs in ACE inhibitors and ARBs and its association with their relative 
market share. METHODS: We used the State Drug Use Data from the Medicaid Drug 
Rebate Program that provides prescription drugs to 46 million low-income Americans. 
We linked the data with the WHO Collaborating Centre for Drug Statistics Methodol-
ogy to obtain Deﬁned Daily Dose (DDD) measurements for drug consumption for 
four large states, for a total of 16 quarters of continuous measurements between 2005 
and 2008. We used a Herﬁndahl-Hirschman Index (HHI) to measure the concentra-
tion in ACE inhibitors and ARBs, by DDD and reimbursements. We conducted mul-
tivariate GLS regression analysis by regressing the HHI on the relative market share 
of ACE inhibitors, adjusted for time trend, the interaction between the HHI and time 
trend, and random effects of states. RESULTS: During the 16 quarters between 2005 
and 2008, the mean concentration index for ACE Inhibitors was 339 (s.d. 71) by 
DDD, 442 (s.d. 148) by reimbursements, and for ARBs 887 (s.d. 277), 693 (s.d. 227) 
by DDD and reimbursements, respectively. The market share of ACE inhibitors was 
negatively associated with the concentration in ARBs (p  0.001, p  0.001), and 
marginally positively associated with the concentration in ACE inhibitors (p  0.05, 
p  0.09), by DDD and reimbursements, respectively. CONCLUSIONS: The relative 
market share of ACE inhibitors and ARBs is cross-linked with concentration of drugs 
within each of these two classes.
